FDA proposes removing semaglutide, tirzepatide and liraglutide from 503B outsourcing list
- On April 30, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list for outsourcing facilities that mass-compound drugs. (fda.gov) - The agency said it found no clinical need for bulk compounding these GLP-1 ingredients, and the public comment window runs through June 30. (fda.gov) - That would tighten a channel already squeezed after FDA declared tirzepatide and semaglutide shortages resolved, pushing demand back toward branded supply. (fda.gov)
GLP-1 compounding just got another big squeeze. The FDA is now proposing to keep semaglutide, tirzepatide, and liraglutide off the 503B bulks list — the list that tells la(fda.gov)a major release valve during the shortage era. Now the agency is saying the legal basis for that route is basically gone. (fda.gov) actually doing? On April 30, 2026, the FDA said it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, and the notice (fda.gov)ne 30, 2026. (fda.gov) ### What is the 503B bulks list? 503B outsourcing facilities are the big compounders — the ones that can make drugs in larger batches for clinics, hospitals, and telehealth-linked channels. But they usually cannot compound from raw active ingredients unless the ingredient is on the 503B b(fda.gov)ry here. (fda.gov) ### Why these three drugs? The FDA says it reviewed the nominations for semaglutide, tirzepatide, and liraglutide and did not find a “clinical need” to let outsourcing facilities k(fda.gov)e that large-scale bulk compounding is medically necessary for patients. (fda.gov) ### Why does this hit now? Because the shortage backdrop changed first. The FDA had already determined tirzepatide shortage conditions were resolved, and it later determined semaglutide shortage conditions were resolved on Fe(fda.gov)goes a step further by targeting the separate 503B bulks pathway too. (fda.gov) ### Does this ban all compounding? No — but it makes the mass-market version much harder. Traditional 503A pharmacies can still compound patient-specific prescriptions in some cases, an(fda.gov)unders that products with the same active ingredient as a commercially available drug can count as “essentially a copy,” even when sellers try to dress them up with add-ons like vitamin B12. (fda.gov) ### Who feels this most? Telehealth platforms, med spas, clinics, and cash-pay channels that relied on out(fda.gov)ed products were hard to find. If this proposal is finalized, more volume likely gets pushed back toward FDA-approved products from Novo Nordisk and Eli Lilly — assuming branded supply really stays steady. That last part is the market risk. (fda.gov) ### Why does liraglutide matter too? Liraglutide is the older, less-hyped GLP-1 in this group, but its inclusion shows the FDA is not j(fda.gov)ss of active ingredients for 503B bulk compounding. (fda.gov) ### Bottom line? This is not just a paperwork move. It is the FDA trying to close a regulatory door that helped create a parallel GLP-1 supply chain. If the proposal sticks, large-scale compounded semaglutide, tirzepatide, and liraglutide become much harder to justify — and the center of gravity shifts back to branded manufacturers. (fda.gov)
